Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Department of Chemical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Adv Exp Med Biol. 2023;1412:175-195. doi: 10.1007/978-3-031-28012-2_9.
Maharashtra was severely affected during the noxious second wave of COVID-19, with the highest number of cases recorded across India. The emergence of new symptoms and dysregulation of multiple organs resulted in high disease severity during the second wave which led to increased difficulties in understanding the molecular mechanisms behind the disease pathology. Exploring the underlying factors can help to relieve the burden on the medical communities to some extent by prioritizing the patients and, at the same time, opening avenues for improved treatments. In the current study, we have performed a mass-spectrometry-based proteomic analysis to investigate the disease pathology using nasopharyngeal swab samples collected from the COVID-19 patients in the Mumbai region of Maharashtra over the period of March-June 2021, the peak of the second wave. A total of 59 patients, including 32 non-severe and 27 severe cases, were considered for this proteomic study. We identified 23 differentially regulated proteins in severe patients as a host response to infection. In addition to the previously identified innate mechanisms of neutrophil and platelet degranulation, this study revealed significant alterations of anti-microbial peptide pathways in severe conditions, illustrating its role in the severity of the infectious strain of COVID-19 during the second wave. Furthermore, myeloperoxidase, cathepsin G, and profilin-1 were identified as potential therapeutic targets of the FDA-approved drugs dabrafenib, ZINC4097343, and ritonavir. This study has enlightened the role of the anti-microbial peptide pathway associated with the second wave in India and proposed its importance in potential therapeutics for COVID-19.
马哈拉施特拉邦在第二波 COVID-19 期间受到了严重影响,是印度记录病例最多的邦。新症状的出现和多个器官的失调导致第二波疾病严重程度增加,这使得人们更难理解疾病病理背后的分子机制。探索潜在因素可以帮助减轻医疗界的负担,通过优先考虑患者,同时为改善治疗方法开辟途径。在目前的研究中,我们使用基于质谱的蛋白质组学分析方法,对 2021 年 3 月至 6 月期间在马哈拉施特拉邦孟买地区采集的 COVID-19 患者的鼻咽拭子样本进行了研究,这是第二波疫情的高峰期。共有 59 名患者(包括 32 名非重症患者和 27 名重症患者)被纳入这项蛋白质组学研究。我们发现 23 种在重症患者中差异调节的蛋白质是宿主对感染的反应。除了先前鉴定的中性粒细胞和血小板脱颗粒的先天机制外,这项研究还揭示了严重情况下抗菌肽途径的显著改变,表明其在第二波期间 COVID-19 传染性株严重程度中的作用。此外,髓过氧化物酶、组织蛋白酶 G 和丝状肌动蛋白-1被鉴定为已批准的药物达巴非尼、ZINC4097343 和利托那韦的潜在治疗靶点。这项研究阐明了与印度第二波相关的抗菌肽途径的作用,并提出了其在 COVID-19 潜在治疗中的重要性。